help button home button Endocrine Society Endocrine Reviews
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints, Permissions and Rights
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cranney, A.
Right arrow Articles by Guyatt, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cranney, A.
Right arrow Articles by Guyatt, G.
Endocrine Reviews 23 (4): 496-507
Copyright © 2002 by The Endocrine Society

Meta-Analyses of Therapies for Postmenopausal Osteoporosis

The Osteoporosis Methodology Group, The Osteoporosis Research Advisory Group

The availability of new therapeutic agents has made clinical decision-making in osteoporosis more complex. Because individual clinicians cannot systematically collect and assimilate all the evidence bearing on the efficacy of osteoporosis therapies, they require summaries for evidence-based decision-making. Systematic reviews using rigorous methods provide an unbiased, comprehensive summary of the available evidence, and meta-analysis provides the most precise possible estimate of the treatment effect. The articles in this series represent systematic reviews of a number of osteoporosis therapies: calcium and vitamin D, the bisphosphonates alendronate and risedronate, hormone replacement therapy, raloxifene, and calcitonin. We used state-of-the-art methodology to provide the most clear and accurate characterization of the effectiveness of these therapies. These include explicit eligibility criteria; a comprehensive search; validity assessment that focused on concealment of randomization, blinding, and completeness of follow-up; and sophisticated analytic methods. In addition, two or more reviewers made independent, reproducible decisions regarding study inclusion and assessments of study validity. Only alendronate and risedronate reduced the risk of both nonvertebral and vertebral fractures. Other agents that reduced vertebral fracture included raloxifene, etidronate, vitamin D, and calcitonin. Clinicians should consider these results when selecting antiosteoporosis therapies for postmenopausal women.

I. Systematic Reviews of Randomized Trials in Osteoporosis: Introduction and Methodology

Ann Cranney, Peter Tugwell, George Wells and Gordon Guyatt , the Osteoporosis Methodology Group, and the Osteoporosis Research Advisory Group

Correspondence: Address all correspondence and requests for reprints to: Dr. Gordon Guyatt, McMaster University, Department of Clinical Epidemiology and Biostatistics, 1200 Main Street West, Room 2C12, Hamilton, Ontario, L8N 3Z5, Canada. E-mail: guyatt{at}McMaster.ca




This article has been cited by other articles:


Home page
 QJMHome page
D.J. Hosking, P. Geusens, and R. Rizzoli
Osteoporosis therapy: an example of putting evidence-based medicine into clinical practice
QJM, June 1, 2005; 98(6): 403 - 413.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
N. H. Bjarnason, A. S. Chan, S. M. Ott, S. L. Ruggiero, B. Mehrotra, H. G. Bone, and A. C. Santora
Ten Years of Alendronate Treatment for Osteoporosis in Postmenopausal Women
N. Engl. J. Med., July 8, 2004; 351(2): 190 - 192.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2002 by The Endocrine Society